CARLSBAD, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Immune Response
Corporation (Nasdaq: IMNR) announces the following Webcast:

     What:     IMNR Presentation at Redchip Partners Fall New York Investor
               Conference 2003

     When:     September 18, 2003 @ 1:00 p.m. Eastern

     Where:    http://www.firstcallevents.com/service/ajwz388762457gf12.html

     How:      Live over the Internet -- Simply log on to the web at the
               address above.

     Contact:  Gwen Rosenberg, Media Contact, 858-759-0759
               Kathy Lane, Investor Contact, 760-771-2236, info@imnr.com

    The Immune Response Corporation is a biopharmaceutical company dedicated
to treating and preventing HIV and AIDS through the development of
immune-based therapeutic vaccines such as REMUNE, its lead product candidate.
The Company was co-founded by medical pioneer Dr. Jonas Salk, who was
instrumental in the formulation of REMUNE, which is currently in Phase II
clinical development.

    HIV, the human immunodeficiency virus, is the virus that causes AIDS, a
condition that slowly destroys the body's immune system, making it vulnerable
to infections.  REMUNE is designed to induce a specific immune response to the
HIV virus.  It is comprised of HIV-1 virus that has been chemically killed and
inactivated so that it is non-infectious, plus an adjuvant that helps enhance
the body's immune response to the virus.  More than 60 million people have
been infected with HIV since it was first recognized in 1981, and
approximately 40 million people around the world are living with HIV today.

    (Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from
http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a
28.8 kbps connection to the Internet.  If you experience problems listening to
the broadcast, send an email to webcastsupport@tfprn.com .)

Link to this page: